In a phase 2, two-stage study, Dr Rebecca Porter discussed the effects of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab on patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer.

The study was conducted on patients with folate receptor-α (FRα) positive recurrent microsatellite stable (MSS) / mismatch repair proficient (pMMR) serous endometrial cancer.

The findings of the study indicated that the combination of mirvetuximab soravtansine and pembrolizumab demonstrated significant activity in pre-treated patients who had a difficult-to-treat form of endometrial cancer.